218 related articles for article (PubMed ID: 36697072)
1. Comparison of the Efficacy and Toxicity of Concurrent Chemoradiotherapy and Durvalumab and Concurrent Chemoradiotherapy Alone for Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Metastasis.
Abe T; Iino M; Saito S; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki YU; Miura YU; Kaira K; Kagamu H; Noda SE; Kato S
Anticancer Res; 2023 Feb; 43(2):675-682. PubMed ID: 36697072
[TBL] [Abstract][Full Text] [Related]
2. Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer in comparison with chemoradiotherapy alone.
Abe T; Saito S; Iino M; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki Y; Miura Y; Kaira K; Kagamu H; Noda SE; Kato S
Thorac Cancer; 2021 Jan; 12(2):245-250. PubMed ID: 33289347
[TBL] [Abstract][Full Text] [Related]
3. Impact of interstitial lung abnormality on survival after adjuvant durvalumab with chemoradiotherapy for locally advanced non-small cell lung cancer.
Kashihara T; Nakayama Y; Okuma K; Takahashi A; Kaneda T; Katagiri M; Nakayama H; Kubo Y; Ito K; Nakamura S; Takahashi K; Inaba K; Murakami N; Saito T; Okamoto H; Itami J; Kusumoto M; Ohe Y; Igaki H
Radiother Oncol; 2023 Mar; 180():109454. PubMed ID: 36640944
[TBL] [Abstract][Full Text] [Related]
4. Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer.
Mayahara H; Uehara K; Harada A; Kitatani K; Yabuuchi T; Miyazaki S; Ishihara T; Kawaguchi H; Kubota H; Okada H; Ninomaru T; Shindo C; Hata A
Radiat Oncol; 2022 Jan; 17(1):7. PubMed ID: 35033139
[TBL] [Abstract][Full Text] [Related]
5. Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer.
Huang Y; Zhao JJ; Soon YY; Wong A; Aminkeng F; Ang Y; Asokumaran Y; Low JL; Lee M; Choo JRE; Chan G; Kee A; Tay SH; Goh BC; Soo RA
Thorac Cancer; 2022 Nov; 13(22):3152-3161. PubMed ID: 36177913
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of post-treatment C-reactive protein-to-albumin ratio in locally advanced non-small cell lung cancer patients receiving durvalumab after chemoradiotherapy.
Araki T; Tateishi K; Komatsu M; Sonehara K; Wasamoto S; Koyama S; Yoshiike F; Hama M; Nishie K; Kondo D; Agatsuma T; Kato A; Takata M; Kanda S; Hanaoka M; Koizumi T
Thorac Cancer; 2022 Jul; 13(14):2031-2040. PubMed ID: 35616056
[TBL] [Abstract][Full Text] [Related]
7. Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study.
Kim DW; Chul Cho B; Pachipala K; Kim SW; Wang CL; Chang GC; Ahn MJ; Alvarez R; Chiu CH; Trigo J; Estival A; Karam SD; O'Brien C; Gowda H; Jiang H; Bauman JE
Lung Cancer; 2024 Apr; 190():107530. PubMed ID: 38471416
[TBL] [Abstract][Full Text] [Related]
8. Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study.
Vokes EE; Mornex F; Sezer A; Cheng Y; Fang J; Baz DV; Cil T; Adjei AA; Ahn MJ; Barlesi F; Felip E; Garon EB; Audhuy F; Ito R; Sato M; Eggleton SP; Martin CM; Reck M; Robinson CG; Paz-Ares L
J Thorac Oncol; 2024 Feb; 19(2):285-296. PubMed ID: 37797733
[TBL] [Abstract][Full Text] [Related]
9. Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer: A multi-center retrospective study.
Tsukita Y; Yamamoto T; Mayahara H; Hata A; Takeda Y; Nakayama H; Tanaka S; Uchida J; Usui K; Toyoda T; Tamiya M; Morimoto M; Oya Y; Kodaira T; Miyauchi E; Jingu K; Sugiura H
Radiother Oncol; 2021 Jul; 160():266-272. PubMed ID: 34023330
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab.
Guggenberger J; Kenndoff S; Taugner J; Käsmann L; Flörsch B; Belka C; Eze C; Manapov F
BMC Cancer; 2022 Mar; 22(1):317. PubMed ID: 35331196
[TBL] [Abstract][Full Text] [Related]
11. Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial.
Tachihara M; Tsujino K; Ishihara T; Hayashi H; Sato Y; Kurata T; Sugawara S; Shiraishi Y; Teraoka S; Azuma K; Daga H; Yamaguchi M; Kodaira T; Satouchi M; Shimokawa M; Yamamoto N; Nakagawa K;
JAMA Oncol; 2023 Nov; 9(11):1505-1513. PubMed ID: 37676681
[TBL] [Abstract][Full Text] [Related]
12. Durvalumab after chemoradiotherapy in patients with stage III non-small-cell lung cancer: real-world outcomes versus clinical trial results.
Verschueren MV; Dijs T; Gulikers JL; Veelen AV; Croes S; Hendriks LE; Smit AA; Bloem LT; Egberts AC; van de Garde EM; Peters BJ
Immunotherapy; 2023 Aug; 15(11):839-851. PubMed ID: 37291888
[TBL] [Abstract][Full Text] [Related]
13. Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab.
Shaverdian N; Thor M; Shepherd AF; Offin MD; Jackson A; Wu AJ; Gelblum DY; Yorke ED; Simone CB; Chaft JE; Hellmann MD; Gomez DR; Rimner A; Deasy JO
Cancer Med; 2020 Jul; 9(13):4622-4631. PubMed ID: 32372571
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab.
Offin M; Shaverdian N; Rimner A; Lobaugh S; Shepherd AF; Simone CB; Gelblum DY; Wu AJ; Lee N; Kris MG; Rudin CM; Zhang Z; Hellmann MD; Chaft JE; Gomez DR
Radiother Oncol; 2020 Aug; 149():205-211. PubMed ID: 32361014
[TBL] [Abstract][Full Text] [Related]
15. Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis.
Sugimoto T; Fujimoto D; Sato Y; Tamiya M; Yokoi T; Taniguchi Y; Hino A; Hata A; Uchida J; Fukuda Y; Hara S; Kanazu M; Matsumoto H; Kokubo M; Yamamoto N
Lung Cancer; 2022 Sep; 171():3-8. PubMed ID: 35863254
[TBL] [Abstract][Full Text] [Related]
16. Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study.
Sugimoto T; Fujimoto D; Sato Y; Tamiya M; Yokoi T; Tamiya A; Iwasawa S; Hata A; Uchida J; Fukuda Y; Hara S; Kanazu M; Hirano K; Kokubo M; Yamamoto N
Invest New Drugs; 2021 Jun; 39(3):853-859. PubMed ID: 33405089
[TBL] [Abstract][Full Text] [Related]
17. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.
Gómez Rueda A; Taus Á; Álvarez Álvarez R; Bernabé-Caro R; Chara L; López-Brea M; Vilà L; Sala González MÁ; Del Barrio Díaz Aldagalán A; Esteban Herrera B; López Castro R; Álvarez Cabellos R; Doménech M; Falagan S; Moreno Vega A; Aguado C; Barba A; Delgado Ureña MT; Isla D; Bellido Hernández L; Fírvida Pérez JL; Juan-Vidal Ó; Massutí B; Mielgo-Rubio X; Ortega AL; Catot S; Dómine M; Escoín-Pérez C; García Navalón F; Gil-Bazo I; Muñoz S; Rodríguez-Abreu D; Villatoro Roldán RM; Alonso-Jáudenes Curbera G; León-Mateos L; Padilla A; Paredes Lario A; Sánchez-Torres JM; Garrido P;
Clin Transl Oncol; 2024 Jul; 26(7):1779-1789. PubMed ID: 38512450
[TBL] [Abstract][Full Text] [Related]
18. Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice.
Yamamoto T; Tsukita Y; Katagiri Y; Matsushita H; Umezawa R; Ishikawa Y; Takahashi N; Suzuki Y; Takeda K; Miyauchi E; Saito R; Katsuta Y; Kadoya N; Jingu K
BMC Cancer; 2022 Apr; 22(1):364. PubMed ID: 35379201
[TBL] [Abstract][Full Text] [Related]
19. Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial.
Garassino MC; Mazieres J; Reck M; Chouaid C; Bischoff H; Reinmuth N; Cove-Smith L; Mansy T; Cortinovis D; Migliorino MR; Delmonte A; Sánchez JG; Chara Velarde LE; Bernabe R; Paz-Ares L; Perez ID; Trunova N; Foroutanpour K; Faivre-Finn C
J Thorac Oncol; 2022 Dec; 17(12):1415-1427. PubMed ID: 35961520
[TBL] [Abstract][Full Text] [Related]
20. Nationwide Real-Life Safety and Treatment Exposure Data on Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III, Locally Advanced, Non-small Cell Lung Cancer: Analysis of Patients Enrolled in the French Early Access Program.
Avrillon V; Daniel C; Boisselier P; Le Péchoux C; Chouaid C
Lung; 2022 Feb; 200(1):95-105. PubMed ID: 35141799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
